|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
|
US20030180290A1
(en)
*
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
WO1997029131A1
(en)
|
1996-02-09 |
1997-08-14 |
Basf Aktiengesellschaft |
HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
|
|
WO1997034633A1
(en)
*
|
1996-03-20 |
1997-09-25 |
Bristol-Myers Squibb Company |
Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
|
|
DE69739725D1
(de)
*
|
1996-11-08 |
2010-02-11 |
Biogen Idec Inc |
Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
|
|
AU8800598A
(en)
*
|
1997-06-20 |
1999-01-04 |
Innogenetics N.V. |
B7-binding molecules for treating immune diseases
|
|
IT1293795B1
(it)
*
|
1997-07-28 |
1999-03-10 |
Angelini Ricerche Spa |
Farmaco attivo nel ridurre la produzione di proteina mcp-1
|
|
NZ514914A
(en)
|
1999-05-07 |
2004-09-24 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
|
CA2379274A1
(en)
*
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Blocking immune response to a foreign antigen using an antagonist which binds to cd20
|
|
US6451284B1
(en)
*
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
|
SE9903895D0
(sv)
*
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
WO2001068133A1
(en)
*
|
2000-03-14 |
2001-09-20 |
Genetics Institute, Inc. |
Use of rapamycin and agents that inhibit b7 activity in immunomodulation
|
|
CA2404365A1
(en)
|
2000-03-31 |
2001-10-11 |
Idec Pharmaceutical Corporation |
Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
|
|
US6379900B1
(en)
|
2000-05-09 |
2002-04-30 |
Conceptual Mindworks, Inc. |
Compositions and methods of use of 8-nitroguanine
|
|
IL152316A0
(en)
*
|
2000-06-09 |
2003-05-29 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and kits for treating transplant rejection
|
|
EP2052742A1
(en)
|
2000-06-20 |
2009-04-29 |
Biogen Idec Inc. |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
|
|
SI1372696T1
(sl)
|
2000-07-03 |
2008-12-31 |
Bristol Myers Squibb Co |
Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
|
|
US20040022787A1
(en)
*
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
MXPA03002262A
(es)
*
|
2000-09-18 |
2003-10-15 |
Idec Pharma Corp |
Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
|
|
HUP0303930A3
(en)
*
|
2001-01-26 |
2012-09-28 |
Univ Emory |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
US6955717B2
(en)
*
|
2001-05-01 |
2005-10-18 |
Medimmune Inc. |
Crystals and structure of Synagis Fab
|
|
US7304033B2
(en)
*
|
2001-05-23 |
2007-12-04 |
Bristol-Myers Squibb Company |
Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
|
|
CA2467363A1
(en)
|
2001-11-16 |
2003-06-12 |
Idec Pharmaceuticals Corporation |
Polycistronic expression of antibodies
|
|
US20040009169A1
(en)
|
2002-02-25 |
2004-01-15 |
Julie Taylor |
Administration of agents for the treatment of inflammation
|
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
|
EP3254673A1
(en)
|
2002-11-13 |
2017-12-13 |
The UAB Research Foundation |
Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
|
|
JP2007501243A
(ja)
*
|
2003-08-04 |
2007-01-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
|
|
JP4745972B2
(ja)
*
|
2003-10-21 |
2011-08-10 |
メルク セローノ ソシエテ アノニム |
クロマチンインスレーターとして作用する極小ｄｎａ配列、及びタンパク質発現におけるその使用
|
|
US20070212301A1
(en)
*
|
2003-11-07 |
2007-09-13 |
Amgen, Inc. |
Monkey Immunoglobulin Sequences
|
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
CN100369931C
(zh)
*
|
2005-04-07 |
2008-02-20 |
苏州大学 |
抗人b7-1分子单克隆抗体及其应用
|
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
|
AU2008296487A1
(en)
|
2007-08-28 |
2009-03-12 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
DK2769729T3
(en)
|
2007-09-04 |
2019-04-23 |
Compugen Ltd |
POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
|
|
ES2836128T3
(es)
|
2008-04-16 |
2021-06-24 |
Univ Johns Hopkins |
Método para determinar variantes del receptor de andrógenos en cáncer de próstata
|
|
SI2483304T1
(sl)
|
2009-09-29 |
2016-08-31 |
F. Hoffmann-La Roche Ag |
Predfiltracijsko naravnavanje pufrskih snovi za močno koncentriran imunoglobulinski pripravek
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
EP2322149A1
(en)
|
2009-11-03 |
2011-05-18 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of ischemia
|
|
EP2338492A1
(en)
|
2009-12-24 |
2011-06-29 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of alzheimer
|
|
CA2790203C
(en)
|
2010-02-19 |
2019-05-14 |
Norman Latov |
Inhibitor of macrophage scavenger receptor 1 (msr1) for the treatment of autoimmune demyelinating diseases
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
GEP201706660B
(en)
|
2010-03-04 |
2017-04-25 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
EP2575818A4
(en)
|
2010-06-03 |
2013-11-06 |
Pharmacyclics Inc |
USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
|
|
MX347734B
(es)
|
2010-06-14 |
2017-05-11 |
Lykera Biomed Sa |
Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
|
|
JP5972871B2
(ja)
|
2010-07-20 |
2016-08-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｉｌ−２３ヘテロ二量体特異的抗体
|
|
PT3722808T
(pt)
|
2010-10-25 |
2024-12-09 |
Biogen Ma Inc |
Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam
|
|
JP2014505462A
(ja)
|
2010-11-10 |
2014-03-06 |
ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム |
高免疫原性のｈｉｖｐ２４配列
|
|
ES2847304T3
(es)
|
2011-01-17 |
2021-08-02 |
Lykera Biomed S A |
Anticuerpos contra la proteína S100P para el tratamiento y diagnóstico de cáncer
|
|
WO2012100835A1
(en)
|
2011-01-28 |
2012-08-02 |
Laboratorios Del Dr. Esteve, S.A. |
Methods and compositions for the treatment of aids
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
CA2836373A1
(en)
|
2011-06-06 |
2012-12-13 |
Neotope Biosciences Limited |
Mcam antagonists and methods of treatment
|
|
US9428574B2
(en)
|
2011-06-30 |
2016-08-30 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
KR101982899B1
(ko)
|
2011-09-30 |
2019-05-27 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
ＴＬ1ａ에 대한 항체 및 그의 용도
|
|
EP2771351B1
(en)
|
2011-10-28 |
2017-06-14 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
|
WO2013114367A2
(en)
|
2012-02-01 |
2013-08-08 |
Compugen Ltd. |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
JP6575950B2
(ja)
|
2012-07-24 |
2019-09-18 |
ファーマサイクリックス エルエルシー |
Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
|
|
WO2014035475A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
TWI595007B
(zh)
|
2012-09-10 |
2017-08-11 |
Neotope Biosciences Ltd |
抗ｍｃａｍ抗體及相關使用方法
|
|
MX2015010023A
(es)
|
2013-02-01 |
2017-11-17 |
Transbio Ltd |
Anticuerpos anti-cd83 y su uso.
|
|
PL2953971T3
(pl)
|
2013-02-07 |
2023-07-03 |
Csl Limited |
Białka wiążące il-11r i ich zastosowania
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
CN105682662A
(zh)
|
2013-03-14 |
2016-06-15 |
马里兰大学巴尔的摩校区 |
雄激素受体减量调节剂及其用途
|
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
CN105873950A
(zh)
|
2013-04-09 |
2016-08-17 |
莱克尔生物医学有限公司 |
用于治疗和诊断癌症的抗s100a7抗体
|
|
BR112016002970A2
(pt)
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
EP2876114A1
(en)
|
2013-11-25 |
2015-05-27 |
Consejo Superior De Investigaciones Científicas |
Antibodies against CCR9 and applications thereof
|
|
EP3074038B1
(en)
|
2013-11-28 |
2019-01-02 |
CSL Limited |
Method of treating diabetic nephropathy
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
ES2851386T3
(es)
|
2013-12-18 |
2021-09-06 |
Csl Ltd |
Método de tratamiento de las heridas
|
|
JP2017509336A
(ja)
|
2014-03-20 |
2017-04-06 |
ファーマサイクリックス エルエルシー |
ホスホリパーゼｃガンマ２及び耐性に関連した変異
|
|
WO2015179404A1
(en)
|
2014-05-19 |
2015-11-26 |
The Johns Hopkins University |
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
|
|
EP3189069B1
(en)
|
2014-07-31 |
2024-10-23 |
UAB Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
|
JP2017523207A
(ja)
*
|
2014-08-08 |
2017-08-17 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用
|
|
CA2959336A1
(en)
|
2014-08-25 |
2016-03-03 |
The Johns Hopkins University |
Methods and compositions related to prostate cancer therapeutics
|
|
AU2015336931B2
(en)
|
2014-10-23 |
2021-04-29 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
|
HK1253533A1
(zh)
|
2015-11-27 |
2019-06-21 |
Csl Limited |
Cd131结合蛋白及其应用
|
|
CN105628935A
(zh)
*
|
2016-03-01 |
2016-06-01 |
广东医学院附属医院 |
一种检测人尿中cd80的试剂盒
|
|
MY198114A
(en)
|
2016-04-15 |
2023-08-04 |
Macrogenics Inc |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
KR20190052027A
(ko)
|
2016-09-23 |
2019-05-15 |
씨에스엘 리미티드 |
응고 인자 결합 단백질 및 이의 용도
|
|
KR101926834B1
(ko)
|
2017-03-21 |
2018-12-07 |
동아에스티 주식회사 |
항-dr5 항체 및 그의 용도
|
|
US20200033347A1
(en)
|
2017-04-18 |
2020-01-30 |
Universite Libre De Bruxelles |
Biomarkers And Targets For Proliferative Diseases
|
|
LT3681911T
(lt)
|
2017-09-11 |
2025-01-10 |
Monash University |
Žmogaus trombino receptorių par4 surišantys baltymai
|
|
KR102715492B1
(ko)
|
2017-10-18 |
2024-10-11 |
씨에스엘 리미티드 |
인간 혈청 알부민 변이체 및 이의 용도
|
|
CA3088676A1
(en)
|
2018-03-23 |
2019-09-26 |
Universite Libre De Bruxelles |
Wnt signaling agonist molecules
|
|
AU2019268410B2
(en)
|
2018-05-16 |
2025-01-02 |
Csl Limited |
Soluble complement receptor type 1 variants and uses thereof
|
|
BR112020025504A2
(pt)
*
|
2018-06-22 |
2021-03-16 |
Junten Bio Co., Ltd. |
Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido
|
|
WO2020116636A1
(ja)
*
|
2018-12-07 |
2020-06-11 |
小野薬品工業株式会社 |
免疫抑制剤
|
|
US20240368259A1
(en)
|
2020-07-17 |
2024-11-07 |
Onena Medicines, S.L. |
Antibodies against lefty proteins
|
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|